GCV Symposium 2017
Skip Content

20 March 2017

Ribo rings up $39m

Suzhou Ribo Life Science, which is developing RNA therapies for hepatitis B, hyperlipidaemia and liver cancer, has secured funding in a Legend Capital-backed series B round.

Author: Robert Lavine, News Editor

China-based drug developer Suzhou Ribo Life Science has raised RMB270m ($39m) in a series B round that included Legend Capital, a subsidiary of conglomerate Legend Holdings, China Money Network reported on Friday.

Subscribe now

Latest Magazine

Editor’s picks

Most popular


23 May 2017

GCV Symposium 2017 - London

Join 400+ business leaders from the corporate venturing and wider high growth business ecosystem for the two-day 2017 GCV Symposium.

11 April 2017

Canadian Corporate Innovation Summit 2017

April 11 to 13, 2017 at the Fairmont Royal York in Downtown Toronto.

23 April 2017

UniVenture Visions 2017 Symposium – Hong Kong

The Coller Institute of Venture and the AUTM Asia 2017 Conference have announced UniVenture Visions, an exclusive symposium that shall trigger the thinking and discussion necessary to evolve research universities…

More events